Welcome to our dedicated page for Evolus news (Ticker: EOLS), a resource for investors and traders seeking the latest updates and insights on Evolus stock.
Evolus Inc (EOLS) is a leading innovator in medical aesthetics, best known for Jeuveau, its FDA-approved botulinum toxin product for cosmetic lines. This page serves as the definitive source for verified Evolus news, providing investors and medical professionals with timely updates on corporate developments.
Access curated press releases and analysis covering regulatory milestones, financial results, and strategic partnerships. Our repository includes updates on aesthetic treatment innovations, market expansion efforts, and clinical research findings specific to Evolus' product pipeline.
Key coverage areas include quarterly earnings disclosures, manufacturing updates, physician adoption trends for Jeuveau, and international distribution agreements. All content is vetted for accuracy and relevance to stakeholders in the self-pay aesthetic sector.
Bookmark this page for efficient tracking of Evolus' performance in the competitive medical beauty market. Check regularly for objective reporting on operational developments and scientific advancements directly from corporate communications.
Evolus reported Q4 2022 net revenue of $43.6 million, a 26% increase from Q4 2021, and a full-year revenue of $148.6 million, up 49% year-over-year. The company reaffirmed its 2023 revenue guidance of $180-$190 million, anticipating growth exceeding the overall U.S. aesthetic neurotoxin market. Jeuveau® remains the fastest-growing neurotoxin in the U.S. with over 700 new customer accounts added in Q4 2022, bringing total accounts to above 9,500. The company aims for a positive non-GAAP operating income in Q4 2023 without requiring additional capital.
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company, will participate in the Barclays Global Healthcare Conference on March 14, 2023, from 2:35 to 3:00 PM ET in Miami Beach, Florida. The event will be accessible via an audio webcast on Evolus' investor relations page at www.evolus.com, with a replay available for 90 days post-event. Evolus aims to revolutionize the aesthetic neurotoxin market with its flagship product, Jeuveau®, a neurotoxin solely dedicated to aesthetics, produced using Hi-Pure™ technology. More details can be found on their official website.
Evolus, Inc. (NASDAQ: EOLS) has launched Nuceiva® in Germany and Austria, marking a significant expansion in the European aesthetic toxin market. This product, approved by the European Commission, targets moderate to severe vertical lines between the eyebrows in adults under 65. The company is partnering with Novvia for distribution in these regions and anticipates entering more European countries and Australia in 2023. The launch follows extensive clinical trials demonstrating the effectiveness of Nuceiva® compared to Botox®. Evolus aims to enhance its market presence and meet growing consumer demand for aesthetic treatments.
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company, will announce its fourth quarter and year-end 2022 financial results on March 8, 2023, after U.S. markets close. Following this announcement, management will host a conference call and live webcast at 4:30 p.m. ET to discuss the results, including a Q&A session. Participants can join the call via phone or the company's Investor Relations website. A replay of the call will be available afterward. Evolus focuses on the aesthetic neurotoxin market and aims to evolve beauty consumer experiences with innovative products like Jeuveau®, its flagship offering.
FAQ
What is the current stock price of Evolus (EOLS)?
What is the market cap of Evolus (EOLS)?
